AKANDA Stock Soars on FTF Telecom Tower Deal and Share Consolidation
By ATTN Desk · Editorial oversight: Sean Han
Introduction
AKANDA CORP (NASDAQ: AKAN) is a London-headquartered, integrated medical cannabis company listed on the NASDAQ Small Cap market. As of December 12, 2025, its shares traded at USD 1.27, reflecting a 61.50% increase on a volume of 4,590,506. The company operates across cultivation, distribution, and corporate segments, with a focus on medical cannabis products in international markets.
Corporate Structure and Experience
Founded to utilize genetic resources, AKANDA employs between 201 and 500 staff and operates cultivation facilities in Canada and Portugal. Its cultivation segment plans to introduce Cookies-branded flower following a genetics partnership with Cookies in 2023. The distribution segment supplies medical cannabis oil and flower—primarily in the United Kingdom—through established sales channels and prescribing doctors. A subsidiary, First Towers & Fiber (FTF), extends the company’s operations into Mexican telecom infrastructure, which provides additional revenue opportunities.
Medical cannabis by Budding .
Developments and News
On October 10, 2025, AKANDA announced that a Canadian postal strike delayed the mailing of proxy materials for its special shareholder meeting, originally set for October 30 and later adjourned to November 28. Between October 16 and 20, AKANDA’s stock rose by 49% after FTF secured a contract for the construction of 20 new telecom towers as part of a USD 7 billion telecom project in Mexico. On November 15, 2025, the company disclosed its efforts to research security requirements for a full cultivation license in British Columbia. A December 2, 2025 SEC Form 6-K revealed shareholder approval for:
- Share consolidation (ratios from 2:1 to 100:1);
- Issuance of 4,775,972 shares to acquire interests in former FTF;
- Issuance of shares to settle related debts.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| 52-Week Range | 0.74 – 9.29 USD |
| Market Cap | 572.7 K USD |
| Revenue (TTM) | 836.7 K USD |
| Net Income (TTM) | –2.4 M USD |
| Profit Margin | –266.3% |
| Total Cash (MRQ) | 2.52 M USD |
| Debt/Equity (MRQ) | 11.85% |
| Price/Earnings (TTM) | 0.03 |
| Beta (5Y Monthly) | 1.65 |
Despite a negative net income and profit margin of –266.3%, AKANDA holds USD 2.52 million in cash against a debt-to-equity ratio of 11.85%. The approved share consolidation aims to improve per-share metrics. The FTF acquisition and associated debt settlements indicate a shift toward infrastructure diversification, while ongoing efforts to secure a full cultivation license reflect the company’s strategy to expand its cannabis operations.
Market Position and Industry Context
AKANDA positions itself within the medical cannabis sector, supplying medicinal-grade products to patients via digital clinics and prescribing physicians. Its partnership with Cookies and planned product launches in Portugal align with industry trends favoring genetics and non-irradiated flower. In the distribution segment, AKANDA competes with established UK suppliers of cannabis oil and flower. The inclusion of a telecom infrastructure segment through FTF represents a strategy to stabilize revenues amid market fluctuations.
tl;dr
On December 2, 2025, shareholders approved AKANDA’s share consolidation (up to 100:1) and issuances totaling 4.8 million shares for the FTF acquisition and debt settlements. Between October 16 and 20, the stock increased by 49% following FTF's contract for 20 new telecom towers in Mexico’s USD 7 billion telecom project. The company is exploring security requirements for a full cultivation license in British Columbia. Looking ahead, AKANDA plans to launch Cookies-branded flower in Portugal and utilize its restructured share base to support renewed investor interest.